On January 22, 2009, Wacker, Dean A.; Rossi, Karen A.; Wang, Ying published a patent.Formula: C7H3BrF3I The title of the patent was Preparation of pyridones as GPR119 G protein-coupled receptor agonists. And the patent contained the following:
The invention is related to pyridones I and II [G = CH, N; Q = C, N; X = CH, N, provided that Q and X are not both N; Y = CH2, NH and derivatives, CO, O, OCH2 and derivatives, S(O)0-2; U = (CH2)n; V = (CH2)m; n, m = independently 0-2; Z = (CH2)q; q = 1-2; R1 = (un)substituted 6-membered monocyclic (hetero)/aryl, 5-membered monocyclic heteroaryl; R2 = (un)substituted cycloalkyl, (hetero)/aryl, heterocyclyl, etc.; R20, R21 = independently H, halo, CN, CO2H, OCF3, haloalkyl, etc.] which are GPR119 G protein-coupled receptor modulators, especially GPR119 G agonists, and are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, arylation of 4-benzyloxy-2(1H)-pyridone with 4-bromophenyl Me sulfone, debenzylation, alkylation of the hydroxypyridinone with tert-Bu 4-[(methylsulfonyl)oxy]piperidine-1-carboxylate (preparation given) gave III. The in vivo modulation of recombinant human GPR119 was determined in a HIT-T15 cAMP assay, human Tet-inducible CAMP assay and luciferase assay (some data given). I, alone, or in combination with another therapeutic agent, are useful for treating diabetes, hyperglycemia, impaired glucose tolerance, obesity, metabolic syndrome, etc. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Formula: C7H3BrF3I
The Article related to pyridone preparation gpr119 g protein coupled receptor agonist diabetes, pyrimidinylpiperidinyloxy pyridone preparation g protein coupled receptor agonist hyperglycemia, oxadiazolylcyclohexyloxy pyridone preparation g protein coupled receptor agonist obesity and other aspects.Formula: C7H3BrF3I
Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com